{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:41:47Z","timestamp":1794534107506,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PON ARS01_00568"],"award-info":[{"award-number":["PON ARS01_00568"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is the second leading cause of death among women after lung cancer. Despite the improvement in prevention and in therapy, breast cancer still remains a threat, both for pre- and postmenopausal women, due to the development of drug resistance. To counteract that, novel agents regulating gene expression have been studied in both hematologic and solid tumors. The Histone Deacetylase (HDAC) inhibitor Valproic Acid (VA), used for epilepsy and other neuropsychiatric diseases, has been demonstrated a strong antitumoral and cytostatic activity. In this study, we tested the effects of Valproic Acid on the signaling pathways involved in breast cancer cells viability, apoptosis and in Reactive Oxygen Species (ROS) production using ER-\u03b1 positive MCF-7 and triple negative MDA-MB-231 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell proliferation assay was performed by MTT Cell cycle, ROS levels and apoptosis were analyzed by flow cytometry, protein levels were detected by Western Blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cell treatment with Valproic Acid reduced cell proliferation and induced G0\/G1 cell cycle arrest in MCF-7 and G2\/M block in MDA-MB-231 cells. In addition, in both cells the drug enhanced the generation of ROS by the mitochondria. In MCF-7 treated cells, it has been observed a reduction in mitochondrial membrane potential, a down regulation of the anti-apoptotic marker Bcl-2 and an increase of Bax and Bad, leading to release of cytochrome C and PARP cleavage. Less consistent effects are recorded in MDA-MB-231 cells, in which the greater production of ROS, compared to MCF-7cells, involves an inflammatory response (activation of p-STAT3, increased levels of COX2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results have demonstrated that in MCF-7 cells the Valproic Acid is a suitable drug to arrest cell growth, to address apoptosis and mitochondrial perturbations, all factors that are important in determining cell fate and health. In a triple negative MDA-MB 231 cells, valproate directs the cells towards the inflammatory response with a sustained expression of antioxidant enzymes. Overall, the not always unequivocal data between the two cellular phenotypes indicate that further studies are needed to better define the use of the drug, also in combination with other chemotherapy, in the treatment of breast tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04015-8","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T12:02:59Z","timestamp":1677758579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner"],"prefix":"10.1186","volume":"21","author":[{"given":"Francesca","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Paol\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Forastiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Amicis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Marrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Daniela","family":"Naimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Panno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"6127","key":"4015_CR1","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1126\/science.1230184","volume":"339","author":"ML Suv\u00e0","year":"2013","unstructured":"Suv\u00e0 ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567\u201370. https:\/\/doi.org\/10.1126\/science.1230184.","journal-title":"Science"},{"key":"4015_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12967-019-2126-6","volume":"17","author":"X Bao","year":"2019","unstructured":"Bao X, Anastasov N, Rosemann WY. novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med. 2019;17:380. https:\/\/doi.org\/10.1186\/s12967-019-2126-6.","journal-title":"J Transl Med"},{"issue":"37","key":"4015_CR3","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","volume":"26","author":"XJ Yang","year":"2007","unstructured":"Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1210599.","journal-title":"Oncogene"},{"issue":"2","key":"4015_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","volume":"74","author":"Y Minamiya","year":"2011","unstructured":"Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer. 2011;74(2):300\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2011.02.019.","journal-title":"Lung Cancer"},{"key":"4015_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lfs.2016.02.092","volume":"151","author":"CL Hsieh","year":"2016","unstructured":"Hsieh CL, Ma HP, Su CM, Chang YJ, Hung WY, Ho YS, Huang WJ, Lin RK. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. Life Sci. 2016;151:7\u201314. https:\/\/doi.org\/10.1016\/j.lfs.2016.02.092.","journal-title":"Life Sci"},{"key":"4015_CR6","doi-asserted-by":"publisher","DOI":"10.1146\/annurevpharmtox-010716-105106","author":"RL Bennett","year":"2018","unstructured":"Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018. https:\/\/doi.org\/10.1146\/annurevpharmtox-010716-105106.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4015_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","volume":"90","author":"CA Krusche","year":"2005","unstructured":"Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and\u20143 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90:15\u201323. https:\/\/doi.org\/10.1007\/s10549-004-1668-2.","journal-title":"Breast Cancer Res Treat"},{"key":"4015_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/1471-2407-13-215","volume":"13","author":"BM Muller","year":"2013","unstructured":"Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer\u2013overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013;13:215. https:\/\/doi.org\/10.1186\/1471-2407-13-215.","journal-title":"BMC Cancer"},{"key":"4015_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4048\/jbc.2014.17.4.323","volume":"17","author":"J Seo","year":"2014","unstructured":"Seo J, Min SK, Park HR, Kim DH, Kwon MJ, Kim LS, Ju YS. Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. J Breast Cancer. 2014;17:323\u201331. https:\/\/doi.org\/10.4048\/jbc.2014.17.4.323.","journal-title":"J Breast Cancer"},{"issue":"2","key":"4015_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","volume":"18","author":"S Landreville","year":"2012","unstructured":"Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0946.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4015_CR11","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/bcr3192","volume":"14","author":"CR Tate","year":"2012","unstructured":"Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79. https:\/\/doi.org\/10.1186\/bcr3192.","journal-title":"Breast Cancer Res"},{"issue":"12","key":"4015_CR12","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.18632\/oncotarget.1314","volume":"4","author":"L Ellis","year":"2013","unstructured":"Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a pten defecient model of prostate cancer. Oncotarget. 2013;4(12):2225\u201336. https:\/\/doi.org\/10.18632\/oncotarget.1314.","journal-title":"Oncotarget"},{"key":"4015_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-016","author":"L Bao","year":"2016","unstructured":"Bao L, Diao H, Dong N, Su X, Wang B, Mo Q, Yu H, Wang X, Chen C. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol. 2016. https:\/\/doi.org\/10.1007\/s10565-016.","journal-title":"Cell Biol Toxicol"},{"key":"4015_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2010.04.002","author":"J Jovanovic","year":"2010","unstructured":"Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol. 2010. https:\/\/doi.org\/10.1016\/j.molonc.2010.04.002.","journal-title":"Mol Oncol"},{"key":"4015_CR15","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/MCB.18.6.3163","volume":"18","author":"M Meyyappan","year":"1998","unstructured":"Meyyappan M, Wong H, Hull C, Riabowol KT. Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol Cell Biol. 1998;18:3163\u201372. https:\/\/doi.org\/10.1128\/MCB.18.6.3163.","journal-title":"Mol Cell Biol"},{"key":"4015_CR16","first-page":"2782","volume":"61","author":"E Evron","year":"2001","unstructured":"Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001;61:2782\u20137.","journal-title":"Cancer Res"},{"key":"4015_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s13148-010-0012-4","author":"JM Wagner","year":"2010","unstructured":"Wagner JM, Hackanson B, L\u00fcbbert M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy epigenetics. Clin. 2010. https:\/\/doi.org\/10.1007\/s13148-010-0012-4.","journal-title":"Clin"},{"key":"4015_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/479364","author":"S Chateauvieux","year":"2010","unstructured":"Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010. https:\/\/doi.org\/10.1155\/2010\/479364.","journal-title":"J Biomed Biotechnol"},{"key":"4015_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1517\/13543784.2013.853037","volume":"22","author":"L Cincarova","year":"2013","unstructured":"Cincarova L, Zdrahal Z, Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs. 2013;22:1535\u201347. https:\/\/doi.org\/10.1517\/13543784.2013.853037.","journal-title":"Expert Opin Investig Drugs"},{"key":"4015_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2174\/156800912800190884","volume":"12","author":"N Tinari","year":"2012","unstructured":"Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets. 2012;12:439\u201352. https:\/\/doi.org\/10.2174\/156800912800190884.","journal-title":"Curr Cancer Drug Targets"},{"issue":"13","key":"4015_CR21","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.2147\/DDDT.S229930.eCollection","volume":"2019","author":"F Giordano","year":"2019","unstructured":"Giordano F, Naimo GD, Nigro A, Romeo F, Paol\u00ec A, De Amicis F, Vivacqua A, Morelli C, Mauro L, Panno ML. Valproic acid addresses neuroendocrine differentiation of LNCaP cells and maintains cell survival. Drug Des Devel Ther. 2019;2019(13):4265\u201374. https:\/\/doi.org\/10.2147\/DDDT.S229930.eCollection.","journal-title":"Drug Des Devel Ther"},{"key":"4015_CR22","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.21873\/anticanres.11077","volume":"36","author":"R Chelluri","year":"2016","unstructured":"Chelluri R, Caza T, Woodford MR, Reeder JE, Bratslavsky G, Byler T. Valproic acid alters angiogenic and trophic gene expression in human prostate cancer models. Anticancer Res. 2016;36:5079\u201386. https:\/\/doi.org\/10.21873\/anticanres.11077.","journal-title":"Anticancer Res"},{"key":"4015_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J Clin. 2018;68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"Cancer J Clin"},{"issue":"1","key":"4015_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/tpj.2011.48","volume":"13","author":"R Soldi","year":"2013","unstructured":"Soldi R, Cohen AL, Cheng L, Sun Y, Moos PJ, Bild AH. A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013;13(1):94\u2013104. https:\/\/doi.org\/10.1038\/tpj.2011.48.","journal-title":"Pharmacogenomics J"},{"issue":"7","key":"4015_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.drudis.2016.05.012","volume":"21","author":"T De Marchi","year":"2016","unstructured":"De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21(7):1181\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2016.05.012.","journal-title":"Drug Discov Today"},{"key":"4015_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pharmthera.2016.07.014","volume":"167","author":"JP Harrelson","year":"2016","unstructured":"Harrelson JP, Lee MW. Expanding the view of breast cancer metabolism: promising molecular targets and therapeutic opportunities. Pharmacol Ther. 2016;167:60\u201373. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.014.","journal-title":"Pharmacol Ther"},{"key":"4015_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19\u201325. https:\/\/doi.org\/10.1016\/j.molonc.2007.01.001.","journal-title":"Mol Oncol"},{"issue":"15","key":"4015_CR28","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.3390\/ijms20153663","volume":"20","author":"A Wawruszak","year":"2019","unstructured":"Wawruszak A, Luszczki JJ, Kalafut J, Okla K, Halasa M, Rivero-Muller A, Stepulak A. Additive pharmacological interaction between cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) in MDA-MB-231 Triple negative breast cancer (TNBC) cells with altered notch1 activity-an isobolographic analysis. Int J Mol Sci. 2019;20(15):3663. https:\/\/doi.org\/10.3390\/ijms20153663.","journal-title":"Int J Mol Sci"},{"key":"4015_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12967-022-03463-y","volume":"20","author":"D Scordamaglia","year":"2022","unstructured":"Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, Zicarelli A, De Rosis S, Giordano F, Miglietta AM, De Francesco EM, Vella V, Belfiore A, Lappano R, Maggiolini M. Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. J Transl Med. 2022;20:263. https:\/\/doi.org\/10.1186\/s12967-022-03463-y.","journal-title":"J Transl Med"},{"issue":"9","key":"4015_CR30","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/cancers12092709","volume":"12","author":"A Nigro","year":"2020","unstructured":"Nigro A, Frattaruolo L, Fava M, De Napoli I, Greco M, Comande A, De Santo M, Pellegrino M, Ricci E, Giordano F, Perrotta I, Leggio A, Pasqua L, Sisci D, Cappello AR, Morelli C. Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells. Cancers. 2020;12(9):2709. https:\/\/doi.org\/10.3390\/cancers12092709.","journal-title":"Cancers"},{"issue":"9","key":"4015_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1746-1596-9-92","volume":"12","author":"JR Eidet","year":"2014","unstructured":"Eidet JR, Pasovic L, Maria R, Jackson CJ, Utheim TP. Objective assessment of changes in nuclear morphology and cell distribution following induction of apoptosis. Diagn Pathol. 2014;12(9):92. https:\/\/doi.org\/10.1186\/1746-1596-9-92.","journal-title":"Diagn Pathol"},{"key":"4015_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jim.2015.04.025","volume":"423","author":"S Pietkiewicz","year":"2015","unstructured":"Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow cytometry with classical annexin v\/propidium iodide staining. J Immunol Methods. 2015;423:99\u2013103. https:\/\/doi.org\/10.1016\/j.jim.2015.04.025.","journal-title":"J Immunol Methods"},{"key":"4015_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.semcancer.2009.02.007","volume":"19","author":"AM Dworkin","year":"2009","unstructured":"Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast:implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19:165\u201371. https:\/\/doi.org\/10.1016\/j.semcancer.2009.02.007.","journal-title":"Semin Cancer Biol"},{"key":"4015_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12967-016-0840-x","volume":"14","author":"E Shin","year":"2016","unstructured":"Shin E, Lee Y, Koo JS. Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology. J Transl Med. 2016;14:87. https:\/\/doi.org\/10.1186\/s12967-016-0840-x.","journal-title":"J Transl Med"},{"key":"4015_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"4015_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.neo.7900101","volume":"2","author":"B Pucci","year":"2000","unstructured":"Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia. 2000;2:291\u20139. https:\/\/doi.org\/10.1038\/sj.neo.7900101.","journal-title":"Neoplasia"},{"key":"4015_CR37","first-page":"5315","volume":"58","author":"I Tamm","year":"1998","unstructured":"Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315\u201320.","journal-title":"Cancer Res"},{"key":"4015_CR38","first-page":"1731","volume":"8","author":"Y Hirohashi","year":"2002","unstructured":"Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8:1731\u20139.","journal-title":"Clin Cancer Res"},{"key":"4015_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/sj.bjc.6600776","volume":"88","author":"SM Kennedy","year":"2003","unstructured":"Kennedy SM, O\u2019Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast. Cancer. 2003;88:1077\u201383. https:\/\/doi.org\/10.1038\/sj.bjc.6600776.","journal-title":"Cancer"},{"key":"4015_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/gut.48.1.137","volume":"48","author":"M Miller","year":"2001","unstructured":"Miller M, Smith D, Windsor A, Kessling A. Survivin gene expression and prognosis in recurrent colorectal cancer. Gut. 2001;48:137\u20138. https:\/\/doi.org\/10.1136\/gut.48.1.137.","journal-title":"Gut"},{"key":"4015_CR41","first-page":"1921","volume":"96","author":"C Adida","year":"2000","unstructured":"Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921\u20135.","journal-title":"Blood"},{"key":"4015_CR42","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.1158\/0008-5472.CAN-05-0491","volume":"65","author":"H Asanuma","year":"2005","unstructured":"Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase\/AKT signaling pathway in breast cancer cells. Cancer Res. 2005;65:11018\u201325. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0491.","journal-title":"Cancer Res"},{"issue":"2","key":"4015_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/life11020105","volume":"11","author":"F Sabbatino","year":"2021","unstructured":"Sabbatino F, Conti V, Liguori L, Polcaro G, Corbi G, Manzo V, Tortora V, Carlomagno C, Vecchione C, Filippelli A, Pepe S. Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients. Life. 2021;11(2):105. https:\/\/doi.org\/10.3390\/life11020105.","journal-title":"Life"},{"key":"4015_CR44","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.3390\/cancers13143409","volume":"13","author":"A Wawruszak","year":"2021","unstructured":"Wawruszak A, Halasa M, Okon E, Kukula-Koch W, Stepulak A. Valproic acid and breast cancer: state of the art in 2021. Cancers. 2021;13:3409. https:\/\/doi.org\/10.3390\/cancers13143409.","journal-title":"Cancers"},{"key":"4015_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cbi.2017.12.003","volume":"280","author":"A Nazl\u0131han","year":"2018","unstructured":"Nazl\u0131han A, Merve E, Elif E, Ul E, AsumanHatice T, Ferda A. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells. Chem Biol Interact. 2018;280:51\u20138. https:\/\/doi.org\/10.1016\/j.cbi.2017.12.003.","journal-title":"Chem Biol Interact"},{"key":"4015_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.7150\/ijbs.5.44","volume":"5","author":"TM Thornton","year":"2009","unstructured":"Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5:44. https:\/\/doi.org\/10.7150\/ijbs.5.44.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"4015_CR47","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/ijms21061913","volume":"21","author":"A Mart\u00ednez-Lim\u00f3n","year":"2020","unstructured":"Mart\u00ednez-Lim\u00f3n A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020;21(6):1913. https:\/\/doi.org\/10.3390\/ijms21061913.","journal-title":"Int J Mol Sci"},{"key":"4015_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4110\/in.2016.16.2.85","volume":"16","author":"HB Low","year":"2016","unstructured":"Low HB, Zhang Y. Regulatory roles of MAPK phosphatases in cancer. Immune Netw. 2016;16:85\u201398. https:\/\/doi.org\/10.4110\/in.2016.16.2.85.","journal-title":"Immune Netw"},{"key":"4015_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/0008-5472.CAN-11-1628","volume":"72","author":"C Cellurale","year":"2012","unstructured":"Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ. Role of JNK in mammary gland development and breast cancer. Cancer Res. 2012;72:472\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1628.","journal-title":"Cancer Res"},{"key":"4015_CR50","doi-asserted-by":"publisher","first-page":"e36389","DOI":"10.7554\/eLife.36389","volume":"7","author":"N Girnius","year":"2018","unstructured":"Girnius N, Edwards YJ, Garlick DS, Davis RJ. The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. Elife. 2018;7:e36389. https:\/\/doi.org\/10.7554\/eLife.36389.","journal-title":"Elife"},{"key":"4015_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12967-020-02267-2","volume":"18","author":"W Li","year":"2020","unstructured":"Li W, Xu M, Li Y, Huang Z, Zhou J, Zhao Q, Le K, Dong F, Wan C, Yi P. Comprehensive analysis of the association between tumor glycolysis and immune\/inflammation function in breast cancer. J Transl Med. 2020;18:92. https:\/\/doi.org\/10.1186\/s12967-020-02267-2.","journal-title":"J Transl Med"},{"key":"4015_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-021-03021-y","volume":"19","author":"L Qiu","year":"2021","unstructured":"Qiu L, Ma Y, Chen X, Zhou L, Zhang H, Zhong G, Zhang L, Tang J. Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway. J Transl Med. 2021;19:344. https:\/\/doi.org\/10.1186\/s12967-021-03021-y.","journal-title":"J Transl Med"},{"key":"4015_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192\u2013203. https:\/\/doi.org\/10.1038\/s12276-020-0384-2.","journal-title":"Exp Mol Med"},{"key":"4015_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1479-5876-8-37","volume":"8","author":"W Xi","year":"2010","unstructured":"Xi W, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909\u2014induced apoptosis of cancer cells. J Transl Med. 2010;8:37.","journal-title":"J Transl Med"},{"key":"4015_CR55","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.ejca.2004.02.031","volume":"40","author":"MF Renschler","year":"2004","unstructured":"Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 2004;40:1934\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2004.02.031.","journal-title":"Eur J Cancer"},{"key":"4015_CR56","doi-asserted-by":"publisher","first-page":"17179","DOI":"10.1074\/jbc.M111604200","volume":"277","author":"S Kotamraju","year":"2002","unstructured":"Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicinmediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277:17179\u201387. https:\/\/doi.org\/10.1074\/jbc.M111604200.","journal-title":"J Biol Chem"},{"key":"4015_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1023\/a:1015331229263","volume":"7","author":"J Yi","year":"2002","unstructured":"Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X. The inherent cellular level of reactive oxygen species: one of the mechanisms determining the apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis. 2002;7:209\u201315. https:\/\/doi.org\/10.1023\/a:1015331229263.","journal-title":"Apoptosis"},{"issue":"2","key":"4015_CR58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","volume":"259","author":"N Fortunati","year":"2008","unstructured":"Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008;259(2):156\u201364. https:\/\/doi.org\/10.1016\/j.canlet.2007.10.006.","journal-title":"Cancer Lett"},{"issue":"3","key":"4015_CR59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/00498254.2019.1618510","volume":"50","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zhen L, Xuanyu W, Ge J, Changliang S, Shuangping L. Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells. Xenobiotica. 2020;50(3):252\u201360. https:\/\/doi.org\/10.1080\/00498254.2019.1618510.","journal-title":"Xenobiotica"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04015-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T12:06:01Z","timestamp":1677758761000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4015"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04015-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the authors have consented to publication of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}